These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32473904)

  • 1. Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.).
    Singh AK; Gupta R; Misra A
    Diabetes Metab Syndr; 2020; 14(5):729. PubMed ID: 32473904
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.).
    Mahajan K; Gaur N
    Diabetes Metab Syndr; 2020; 14(5):723-724. PubMed ID: 32473902
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to the letter of Singh and Singh in response to the article: "Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis" (Kumar et al.).
    Kumar A; Arora A; Sharma P; Anikhindi SA; Bansal N; Singla V; Khare S; Srivastava A
    Diabetes Metab Syndr; 2020; 14(5):1147-1148. PubMed ID: 32668400
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter in response to letter to the editor by Singh and Dhibar regarding the article "COVID-19: From bench to bedside" (Singh et al.).
    Singh A; Shaikh A; Singh R; Singh AK
    Diabetes Metab Syndr; 2020; 14(5):865. PubMed ID: 32562863
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections.
    Speth RC
    Drug Dev Res; 2020 Sep; 81(6):643-646. PubMed ID: 32304146
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Letter to the Editor: "Don't judge too RAShly: the multifaceted role of the renin-angiotensin system and its therapeutic potential in COVID-19".
    Abassi ZA; Skorecki K; Heyman SN; Kinaneh S; Armaly Z
    Am J Physiol Lung Cell Mol Physiol; 2020 May; 318(5):L1029-L1030. PubMed ID: 32364440
    [No Abstract]   [Full Text] [Related]  

  • 7. Renin-Angiotensin-Aldosterone System Inhibitors Impact on COVID-19 Mortality: What's Next for ACE2?
    Patel AB; Verma A
    Clin Infect Dis; 2020 Nov; 71(16):2129-2131. PubMed ID: 32442259
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter to the Editor - Circulating plasma levels of angiotensin II and aldosterone in patients with coronavirus disease 2019 (COVID-19): A preliminary report.
    Henry BM; Benoit S; Lippi G; Benoit J
    Prog Cardiovasc Dis; 2020; 63(5):702-703. PubMed ID: 32659343
    [No Abstract]   [Full Text] [Related]  

  • 9. [Scientific statement on using of renin angiotensin system blockers in patients with cardiovascular disease and COVID-19].
    ;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Jul; 48(7):565-566. PubMed ID: 32842268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Renin-Angiotensin system and SARS-CoV-2 infection: A role for the ACE2 receptor?
    Sever P; Johnston SL
    J Renin Angiotensin Aldosterone Syst; 2020; 21(2):1470320320926911. PubMed ID: 32403977
    [No Abstract]   [Full Text] [Related]  

  • 11. COVID-19, Renin-Angiotensin System, and Hematopoiesis.
    Çiftçiler R; Haznedaroğlu İC
    Turk J Haematol; 2020 Aug; 37(3):207-208. PubMed ID: 32394689
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.
    Zhou F; Liu YM; Xie J; Li H; Lei F; Yang H; Qin JJ; Cai J; Zhang XJ; Wu B; Xia M; Xiang D; Yang C; Ma X; Xu Q; Lu Z; Lu H; Xia X; Wang D; Liao X; Peng G; Yang J; Huang X; Zhang BH; Yuan Y; Wei X; Liu PP; Wang Y; Zhang P; She ZG; Xia J; Li H
    Hypertension; 2020 Aug; 76(2):e15-e17. PubMed ID: 32493070
    [No Abstract]   [Full Text] [Related]  

  • 13. Letter to editor in response to "COVID-19: From bench to bedside" by Singh A et al.
    Singh H; Prasad Dhibar D
    Diabetes Metab Syndr; 2020; 14(5):815-816. PubMed ID: 32540734
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hypertension, RAAS blockade and risk in COVID-19 patients].
    Spaak J; Kahan T
    Lakartidningen; 2020 Jun; 117():. PubMed ID: 32594472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What Kind of Evidence Is Needed to Dictate Practice Regarding Inhibitors of the Renin-Angiotensin System in COVID-19?
    Elijovich F; Laffer CL
    Hypertension; 2020 Sep; 76(3):665-669. PubMed ID: 32783759
    [No Abstract]   [Full Text] [Related]  

  • 16. Authors' Reply.
    Batlle D; Soler MJ; Welling PA; Swaminathan S;
    J Am Soc Nephrol; 2020 Aug; 31(8):1918-1919. PubMed ID: 32636207
    [No Abstract]   [Full Text] [Related]  

  • 17. 5 classes of antihypertensive drugs were not linked to positive COVID-19 test results or severe COVID-19.
    Fekete T
    Ann Intern Med; 2020 Sep; 173(6):JC35. PubMed ID: 32926815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there enough evidence to discontinue the renin-angiotensin system inhibitors in patients with COVID-19?
    Bobkova I; Kamyshova E; Rudenko T; Stavrovskaya E; Moiseev S
    Med Hypotheses; 2020 Oct; 143():109888. PubMed ID: 32480248
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Siniorakis et al., "COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure".
    Fedson DS; Opal SM; Rordam OM
    mBio; 2020 May; 11(3):. PubMed ID: 32471831
    [No Abstract]   [Full Text] [Related]  

  • 20. COVID-19 and Renin Angiotensin Blockers: Current Evidence and Recommendations.
    Messerli FH; Siontis GCM; Rexhaj E
    Circulation; 2020 Jun; 141(25):2042-2044. PubMed ID: 32282224
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.